Patients
paranoia, dementia, visual impairment, psychiatric, schizophrenia
MOTION SICKNESS, DISEASE, SEVERE ACUTE RESPIRATORY SYNDROME
The Swiss Association of Research Ethics Committees approved the study protocol (BASEC-ID 2020–00728) and it was registered on ClinicalTrials.gov (identifier NCT04561596).For enrollment, we considered all consecutive patients over 18 years old and referred to the radiology department for peripheral endovascular interventions (EVI) under local anesthesia (angiography, phlebography, arterial intervention, and venous intervention). Candidates were excluded if they had limited language comprehension, important visual impairment, or were deaf. We also excluded those with a history of motion sickness or psychiatric disease (paranoia, schizophrenia, deep water phobia, dementia), or if they required sedative medication. As the study was conducted during the COVID-19 pandemic, we also excluded all patients with severe acute respiratory syndrome.